Feb 09, 2016 13:10 pm UTC| Business
DUBLIN, Feb. 09, 2016 -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced...
Feb 09, 2016 13:03 pm UTC| Business
WARREN, N.J., Feb. 09, 2016 -- Bellerophon Therapeutics,Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced positive data from the final analysis of the Company’s Phase 2 long-term extension...
RedHill Biopharma Issues Letter to Shareholders
Feb 09, 2016 13:00 pm UTC| Business
TEL-AVIV, Israel, Feb. 09, 2016 -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), an Israeli biopharmaceutical company primarily focused on the development and commercialization of late...
Ultragenyx to Present at the Leerink Partners Annual Healthcare Conference
Feb 09, 2016 13:00 pm UTC| Business
NOVATO, Calif., Feb. 09, 2016 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini...
Xenon Names Dr. James R. Empfield Senior Vice President, Drug Discovery
Feb 09, 2016 13:00 pm UTC| Business
BURNABY, British Columbia, Feb. 09, 2016 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. James R. Empfield has been named as Senior Vice President, Drug...
Asta Funding, Inc. Announces Earnings for First Quarter Fiscal 2016
Feb 09, 2016 13:00 pm UTC| Business
Total Income $12.3 million, an Increase of 18% from prior yearIncreased Revenues Reported in All Business SegmentsNet Income Attributable to Asta Funding of $1.8 Million, or $0.15 Per Diluted ShareStrong Balance Sheet, No...
Feb 09, 2016 13:00 pm UTC| Business
SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 09, 2016 -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported positive topline data from three ongoing Phase 1 oncology...